Johnson & Johnson to Acquire TARIS Biomedical for its Drug Delivery Technology to Treat Bladder Cancer
Shots:
- J&J acquires TARIS Biomedical while TARIS to continue research in Lexington- Massachusetts and will also become part of Janssen R&D's Oncology Therapeutic Area. Additionally- the companies will focus on optimization of drug candidates for advancing and delivering future clinical programs utilizing TARIS technology
- The focus of an acquisition is to utilize TARIS’ drug delivery technology for advancing TAR-200 candidate further strengthening targeted oncologic therapy approach
- TARIS’ TAR-200 is an investigational candidate designed to release chemotherapeutic agent gemcitabine continuously in bladder for multiple weeks and has also received FDA’s Fast Track Designation in patients with organ-confined or locally advanced MIBC who are unfit for curative-intent therapy
Click here to read full press release/ article | Ref: PRNewswire | Image: Signbox
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com